Alzamend Neuro (NASDAQ:ALZN) Shares Up 18.8% – Here’s What Happened

Posted by Geri Gentry on May 21st, 2026

Shares of Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) were up 18.8% on Wednesday . The stock traded as high as $1.25 and last traded at $1.20. Approximately 175,266 shares changed hands during mid-day trading, an increase of 339% from the average daily volume of 39,899 shares. The stock had previously closed at $1.01.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded Alzamend Neuro from a “sell (e+)” rating to a “sell (e)” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.00.

Get Our Latest Research Report on ALZN

Alzamend Neuro Trading Up 18.8%

The stock has a market capitalization of $4.56 million, a P/E ratio of -0.56 and a beta of 0.11. The business has a 50-day moving average price of $1.27 and a 200 day moving average price of $1.83.

Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last posted its earnings results on Wednesday, March 11th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.05). On average, sell-side analysts predict that Alzamend Neuro, Inc. will post -2.58 earnings per share for the current fiscal year.

Insider Transactions at Alzamend Neuro

In related news, Director Milton C. Ault III purchased 108,388 shares of the stock in a transaction that occurred on Tuesday, April 14th. The stock was bought at an average cost of $1.00 per share, for a total transaction of $108,388.00. Following the completion of the transaction, the director directly owned 116,648 shares in the company, valued at $116,648. This represents a 1,312.20% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 1.39% of the stock is currently owned by corporate insiders.

Institutional Trading of Alzamend Neuro

A hedge fund recently raised its stake in Alzamend Neuro stock. Geode Capital Management LLC increased its stake in Alzamend Neuro, Inc. (NASDAQ:ALZN – Free Report) by 33.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 27,506 shares of the company’s stock after buying an additional 6,928 shares during the quarter. Geode Capital Management LLC owned about 0.72% of Alzamend Neuro worth $50,000 as of its most recent SEC filing. 49.61% of the stock is owned by hedge funds and other institutional investors.

About Alzamend Neuro

(Get Free Report)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.